NewLimit’s $435M Megaround; Lilly’s Busy Dealmaking Week

Coinbase CEO's anti-aging startup NewLimit is raising $435 million, tripling its valuation

The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year

NewLimit’s $435M megaround; Lilly’s busy dealmaking week

The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.

Longevity startup NewLimit raises $435 million ahead of first clinical trial

Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding. NewLimit announced its plans and Series C fundraising Tuesday. Founders Fund, the noted Silicon Valley venture capital firm co-founded by Peter Thiel, led the financing, which also included Thrive Capital, Lilly Ventures, and money from tech entrepreneurs Nat Friedman and Daniel Gross. The company is now…

Coinbase CEO Brian Armstrong's Newlimit Raises $435 Million, Tripling Valuation to $3.1 Billion

Newlimit, the longevity biotech co-founded by Coinbase CEO Brian Armstrong, has raised $435 million in a Series C round led by Founders Fund, roughly tripling the company’s valuation to about $3.1 billion. Crypto Wealth Flows Into Longevity Science Newlimit, the anti-aging biotech co-founded by Coinbase Global Inc. (Nasdaq: COIN) Chief Executive Brian Armstrong, has closed […]

Brian Armstrong’s NewLimit Raises $435M for Human Trials

NewLimit raised $435M in Series C funding led by Founders Fund to advance its first age-reprogramming drug into human trials.

NewLimit Series C: Armstrong-Backed Longevity Startup Raises $435M

TLDR: NewLimit Series C raised $435M led by Founders Fund for longevity biotech expansion and clinical readiness. Startup targets epigenetic reprogramming therapies aimed at restoring youthful function in aged human cells. First-in-human trials for lead liver cell program are planned for next year after recent breakthrough results. Funding brings major VC backing as NewLimit scales research toward regulated human clinical applications. NewLimit…